Alterity and UniQuest partner to reverse bacterial resistance to antibiotics-PR Newswire APAC

New commercial opportunity for PBT2

Alterity and UniQuest partner to reverse bacterial resistance to antibiotics-PR Newswire APAC

MELBOURNE, Australia, Dec. 22, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced it has been granted a licence by UniQuest, the commercialisation company of The University of Queensland (UQ), to novel zinc ionophore technology to combat...

Read more: Alterity and UniQuest partner to reverse bacterial resistance to antibiotics-PR Newswire APAC

More Articles …

  1. Home is Where the Heart is for Students, GSA Reveals-PR Newswire APAC
  2. VeChain Foundation Announces Partnership With the Royal Melbourne Institute of Technology (RMIT) Blockchain Innovation Hub, Accelerating Blockchain Governance Research
  3. China Matters Documents Speed and Innovation of China's Express Delivery-PR Newswire APAC
  4. Vinamilk named "ASEAN Asset Class" and Vietnam's Top Listed Company for Corporate Governance-PR Newswire APAC
  5. Equities First Holdings Rebrand Marks Ambitious Growth Plans-PR Newswire APAC
  6. iQIYI's 'Mist Theater' Goes Global, to Be Aired in South Korea, Australia and Vietnam-PR Newswire APAC
  7. ValueLabs wins IBSI Global Fintech Innovation Award-PR Newswire APAC
  8. Research on preventative nasal spray, which protects against COVID-19 and common cold, published in leading peer-reviewed academic journals
  9. Small vessels can cause big problems; MagicTouch SCB Granted 'Breakthrough Device Designation' for the treatment of Small Coronary Artery Lesions
  10. Crypto.com Chain Prepares for Mainnet Launch with Final Dry Run